Nearly Half of GLP-1 Users Are Changing Their Own Doses in 2026: What the New CDC Report Means for Your Weight Loss

The report draws on the CDC's Rapid Surveys System, which polled 8,118 U.S. adults in July and August 2025 through two national probability panels. The headline numbers paint the clearest picture yet of how widespread GLP-1 use has become — and how often real-world use drifts from the prescription label.

About 9.8% of U.S. adults reported taking a GLP-1 medication such as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) in the past 12 months. Use was higher among women (11.9%) than men (7.6%), and peaked among adults aged 40 to 64 at 13.7%. Among adults with class 3 obesity, nearly 1 in 4 (24.1%) reported using one of these medications.

The striking finding is what happened after the prescription was filled. Roughly 44% of users said they modified their medication use — and 28% reported skipping doses, the single most common change. Younger adults modified the most: 54% of users aged 18 to 39 changed their regimen, compared with 30% of those 65 and older. As Becker's Hospital Review noted in its coverage, this is the first federal snapshot of how Americans are really using these drugs, not just how many are taking them.

Among users who changed how they take their medication, 38% cited cost and 36% cited availability as the reason. The cost pressure lands hardest on younger patients: 58% of 18-to-39-year-olds who modified their use blamed price, versus just 20% of seniors. Bloomberg's reporting on the data framed it plainly: users are skipping doses and stretching supply to cope with what these medications cost out of pocket.

That pattern will sound familiar if you have followed the coverage fights of the past year. Many employer plans have trimmed GLP-1 benefits, and even insured patients can face high copays or sudden formulary changes mid-treatment. When a medication works but the budget doesn't, patients improvise — and that improvisation is exactly what the CDC is now measuring.

One of the report's more surprising findings: 22.6% of GLP-1 users said they were taking a compounded version of the drug, and another 8.8% didn't know whether theirs was compounded or brand-name. Users of compounded versions were far more likely to modify their dosing — 62% did, compared with 36% of those on brand-name products.

That gap matters. Compounded GLP-1s typically come in multi-dose vials drawn up with a syringe, which makes improvised dosing easy in a way a fixed-dose pen does not. The CDC report notes existing concerns from the FDA and the American Diabetes Association about the safety, quality, and consistency of compounded GLP-1 products. If you use a compounded medication, the source matters enormously: it should come from a licensed, state-regulated pharmacy through a legitimate prescriber relationship — not a gray-market website or an unregulated "research peptide" seller.

GLP-1 medications work best at steady, consistent exposure. Semaglutide and tirzepatide are weekly injections precisely because their levels are designed to stay stable between doses. When you skip weeks or stretch the interval, drug levels dip, appetite suppression fades, and the hunger and "food noise" the medication was quieting can return before your next injection.

There are practical downsides beyond slower weight loss. Restarting after a long gap can mean re-experiencing the nausea, constipation, and fatigue that are common when a dose is new, because your body loses the tolerance it built up. And about 12% of users in the CDC survey said they cut back or stopped because of side effects — a problem that is often better solved with a provider-guided dose adjustment or supportive medication than with silent skipping. The CDC itself flags that the safety and effectiveness of these real-world, off-label modifications simply haven't been studied, which is researcher language for: nobody knows what results you are actually getting at the dose you invented.

None of this means dose flexibility is always wrong — maintenance strategies and slower titration schedules are real tools. The difference is that they should be designed with a licensed provider who knows your history, your labs, and your goals, not improvised at the kitchen counter.

The encouraging news in late 2026 is that the price landscape is finally moving. Both major manufacturers have agreed to lower U.S. prices on their weight loss drugs under deals announced by the federal government, and self-pay pathways now exist that didn't two years ago. Before stretching doses on your own, it's worth exhausting the legitimate options: ask your provider about staying at a lower effective dose rather than skipping a higher one, check whether your plan's formulary changed at renewal, compare manufacturer direct-pay programs, and look at telehealth-based options that bundle the prescription, the medication, and follow-up into one predictable monthly cost.

A provider who knows cost is the issue can often build a plan around it. What they can't do is fix a regimen they don't know you've changed — so if you have been modifying your doses, say so at your next visit. It is common enough now that the CDC has a statistic for it.

If you are weighing GLP-1 treatment — or trying to stay on it without gambling on skipped doses — JoeyMed's licensed providers can help you find a plan that fits both your health goals and your budget. Our weight loss program includes options like TIRZ HD, with transparent pricing, provider-guided titration, and check-ins that catch problems before they derail your progress. If side effects like nausea are what's pushing you to skip doses, ask about anti-nausea support as part of your plan. Every treatment decision is made with a licensed provider after a health screening, because these medications aren't right for everyone — and the right dose is one you can actually stay on.